| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.3M | — | — |
| SG&A Expense | $927K | — | +574.6% |
| Operating Income | -$3.2M | — | -2216.0% |
| Net Income | -$3.2M | — | -2189.7% |
| EPS (Basic) | -$0.11 | — | -1000.0% |
| EPS (Diluted) | -$0.11 | — | -1000.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.0M | -20.0% | — |
| Current Assets | $8.1M | -27.9% | — |
| Total Assets | $8.4M | -27.4% | — |
| Current Liabilities | $129K | -6.1% | — |
| Total Liabilities | $333K | -7.9% | — |
| Stockholders' Equity | $8.1M | -28.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$955K | — | -536.6% |
| Financing Cash Flow | $200K | — | +0.0% |